Novel Peptide-Drug Conjugate Melphalan Flufenamide - A story of a successful industry-academia collaboration
12:00 til 13:00
BMC Seminar Friday 3rd of September, 12:00 in Læknagarður room 201
Speaker: Dr. Ana Slipicevic, Oncopeptides AB, Sweden
Title: Novel Peptide-Drug Conjugate Melphalan Flufenamide - A story of a successful industry-academia collaboration
Zoom link: https://eu01web.zoom.us/j/67319859829
Bio: Ana Slipicevic Ph.D. Translational research Director at Oncopeptides AB. She is responsible for the preclinical development of lead compounds and the implementation of translational research strategies in early clinical development. Before joining Oncopeptides AB, she was principal investigator in vivo pharmacology at Medivir AS as well as a researcher at the Department of Pathology, Oslo University Hospital, where she was leading a research group focusing on basic biology and therapy of melanoma.
Dr. Ana Slipicevic, Oncopeptides AB, Sweden
